Clinical efficacy of compound sulfamethoxazole combined with budesonide on pertussis syndrome in children
Objective:To investigate the clinical efficacy of compound sulfamethoxazole combined with budesonide in treating pertussis syndrome in children.Methods:A total of 60 children with pertussis syndrome admitted from January 2022 to April 2024 were selected and randomly divided into a control group and an observation group(n=30)according to a random number table method.They were treated with budesonide 1 mL nebulized inhalation therapy combined with erythromycin 20 mg·(kg·d)-1 intravenous injection or compound sulfamethoxazole 20 mg·(kg·d)-1 oral administration.The clinical efficacy was evaluated after 7 days of treatment,and the time of changes in clinical symptoms during the treatment period was observed.Pulmonary function indicators were measured using a pulmonary function tester before and after treatment,and inflammatory indicators were measured using enzyme-linked immunosorbent assay.Immune function indicators were measured using immunoturbidimetry.Results:The total effective rate of the observation group was higher than that of the control group(P<0.05).After treatment,the observation group showed a shorter symptom relief time,lower levels of Interleukin(IL)-6,IL-17,and C-reactive protein(CRP)compared to the control group(P<0.05),while all pulmonary function indicators and levels of immunoglobulin(Ig)A,IgG,and IgM were higher than those in the control group(P<0.05).Conclusion:The treatment of children with pertussis syndrome based on budesonide combined with compound sulfamethoxazole tablets can effectively enhance their lung function and immune function,alleviate the body's inflammatory response,and its efficacy is superior to that of erythromycin.
Pertussis syndrome in childrenCompound sulfamethoxazoleBudesonideLung functionInflammatory indicators
NETL
NSTL
万方数据
